Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Gastroenterology

Volumn 151, Issue 3, 2016, Pages 457-471.e5

  Ioannou, George N ^a,b   Beste, Lauren A ^a,c   Chang, Michael F ^d,e   Green, Pamela K ^a   Lowy, Elliott ^a   Tsui, Judith I ^c   Su, Feng ^c   Berry, Kristin ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

DAA; Harvoni; VA; Viekira

Indexed keywords

BOCEPREVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL; URIDINE PHOSPHATE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; CAUCASIAN; CLINICAL EFFECTIVENESS; COMBINATION DRUG THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NONHUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VETERANS HEALTH; VIRUS LOAD; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; GENETICS; GENOTYPE; GOVERNMENT; HEPACIVIRUS; LIVER CIRRHOSIS; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; VIROLOGY;

AGED; ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARBAMATES; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITONAVIR; SOFOSBUVIR; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; URACIL; URIDINE MONOPHOSPHATE;

EID: 84995477394     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.05.049     Document Type: Article

References (39)

1. 1 Andreone, P., Colombo, M.G., Enejosa, J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365 e1.
2. 2 Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370 (2014), 1983–1992.
3. 3 Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
4. 4 Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
5. 5 Zeuzem, S., Jacobson, I.M., Baykal, T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1604–1614.
6. 6 Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
7. 7 Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
8. 8 Feld, J.J., Kowdley, K.V., Coakley, E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1594–1603.
9. 9 Naggie, S., Cooper, C., Saag, M., et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373 (2015), 705–713.
10. 10 Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
11. 11 Gane, E.J., Hyland, R.H., An, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461 e1.
12. 12 Beste, L.A., Green, P.K., Ioannou, G.N., Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Eur J Gastroenterol Hepatol 27 (2015), 123–129.
13. 13 Ioannou, G.N., Beste, L.A., Green, P.K., Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 12 (2014), 1371–1380.
14. 14 Backus, L.I., Boothroyd, D.B., Phillips, B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46 (2007), 37–47.
15. 15 Beste, L.A., Ioannou, G.N., Prevalence and treatment of chronic hepatitis C Virus infection in the US Department of Veterans Affairs. Epidemiol Rev 37 (2015), 131–143.
16. 16 Ioannou, G.N., Scott, J.D., Yang, Y., et al. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Aliment Pharmacol Ther 38 (2013), 1373–1384.
17. 17 Sterling, R.K., Kuo, A., Rustgi, V.K., et al. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther 41 (2015), 671–685.
18. 18 US Department of Veterans Affairs. Health services research and development. http://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm. Accessed February 10, 2016.
19. 19 Kramer, J.R., Giordano, T.P., Souchek, J., et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C. Am J Gastroenterol 100 (2005), 56–63.
20. 20 Ioannou, G.N., Splan, M.F., Weiss, N.S., et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 938–945.
21. 21 Davila, J.A., Henderson, L., Kramer, J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 154 (2011), 85–93.
22. 22 Ioannou, G.N., Bryson, C.L., Weiss, N.S., et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 57 (2013), 249–257.
23. 23 Kramer, J.R., Davila, J.A., Miller, E.D., et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 27 (2008), 274–282.
24. 24 Beste, L.A., Leipertz, S.L., Green, P.K., et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans, 2001–2013. Gastroenterology 149 (2015), 1471–1482 e5.
25. 25 Kramer, J.R., Kanwal, F., Richardson, P., et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 106 (2011), 483–491.
26. 26 Beste, L.A., Ioannou, G.N., Larson, M.S., et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 8 (2010), 972–978.
27. 27 Kanwal, F., Hoang, T., Kramer, J.R., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140 (2011), 1182–1188 e1.
28. 28 Miller, D.R., Safford, M.M., Pogach, L.M., Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 27:Suppl 2 (2004), B10–B21.
29. 29 Vallet-Pichard, A., Mallet, V., Nalpas, B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46 (2007), 32–36.
30. 30 Yoshida, E.M., Sulkowski, M.S., Gane, E.J., et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 61 (2015), 41–45.
31. 31 McCaffrey, D.F., Griffin, B.A., Almirall, D., et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 32 (2013), 3388–3414.
32. 32 HCV Guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA. Available at: http://www.hcvguidelines.org. Accessed January 25, 2016.
33. 33 Harvoni Package Insert. Available at: https://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed January 26, 2016.
34. 34 Chronic hepatitis C virus (HCV) infection: treatment considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and National Viral Hepatitis Program. Available at: http://www.hepatitis.va.gov/provider/index.asp. Accessed January 26, 2016.
35. 35 Brown, R.S. Jr., O'Leary, J.G., Reddy, K.R., et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl 22 (2016), 24–33.
36. 36 Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
37. 37 Foster, G.R., Irving, W.L., Cheung, M.C., et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
38. 38 Backus, L.I., Belperio, P.S., Shahoumian, T.A., et al. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology, 2016 Apr 26 [Epub ahead of print] http://dx.doi.org/10.1002/hep.28625.
39. 39 Nezam A, Bacon BR, Dieterich DT, et al. Failure with all-oral regimens: academic and community treatment of a real-world population from the TRIO Network. The Liver Meeting 2015, Late Breaking Abstract 17, November 16, 2015, The Liver Meeting, San Francisco, CA.2016.